Intra-articular anti-tumor necrosis factor α antibody in recalcitrant arthritis of Behçet's disease [4]

Clinical and Experimental Rheumatology

Volumn 21, Issue 4 SUPPL. 30, 2003, Pages

  Andonopoulos, Andrew P ^a   Meimaris, N ^a   Daoussis, D ^a   Bounas, A ^a   Yiannopoulos, G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTHRITIS; BEHCET DISEASE; CASE REPORT; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; HUMAN; LETTER; MALE; OUTCOMES RESEARCH; PARACENTESIS; PATHOGENESIS; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BEHCET SYNDROME; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HUMANS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141669154     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
2. TARGAN SR, HANAUER SR, VAN DEVENTER SJH et al.: A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Chron's disease. N Engl J Med 1997; 337: 1029-35.
3. SCHOPF RE, AUST H, KNOP J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J An Acad Dermatol 2002; 46: 886-91.
4. WOLLINA U, KONRAD H: Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis-alpha antibody. J Eur Acad Dermatol Venereol 2002; 16: 127-9.
5. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 1187-93.
6. SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI CG, KAKLAMANIS P, MARKOMICHELAKIS NN: Effect of infliximab in sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295-6.
7. TRAVIS SP, CZAJKOWSKI M, McGOVERN DP, WATSON RG, BELL AL: Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49: 725-8.
8. KELLNER H, KROETZ M, SCHATTENKIRCHNER M, KELLNER W: Successful therapy of sacroiliitis in AS patients by intraarticular injection of infliximab. Arthritis Rheum 2002; 46 (Suppl.): abstr. 1127.
9. DREHER R, FLAIG W, LEITZKE D: Treatment of rheumatoid arthritis by intraarticular injections with TNF alpha blockers. Arthritis Rheum 2001; 45 (Suppl.): abstr. BRC15.
10. YAMASHITA N, KANEOKA H, KANEKO S et al.: Role of γδT lymphocytes in the development of Behcet's disease. Clin Exp Immunol 1997; 107: 241-7.